Crinetics Pharmaceuticals Stock Performance
CRNX Stock | USD 49.38 1.45 3.03% |
On a scale of 0 to 100, Crinetics Pharmaceuticals holds a performance score of 10. The firm shows a Beta (market volatility) of 2.53, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Crinetics Pharmaceuticals will likely underperform. Please check Crinetics Pharmaceuticals' sortino ratio, as well as the relationship between the semi variance and rate of daily change , to make a quick decision on whether Crinetics Pharmaceuticals' price patterns will revert.
Risk-Adjusted Performance
10 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Crinetics Pharmaceuticals are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unfluctuating basic indicators, Crinetics Pharmaceuticals showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 3.03 | Five Day Return (0.10) | Year To Date Return 39.53 | Ten Year Return 101.47 | All Time Return 101.47 |
1 | Crinetics Pharmaceuticals Announces Oversubscribed 350 Million Private Placement | 02/28/2024 |
2 | Insider Sell COO Jeff Knight Sells 32,359 Shares of Crinetics Pharmaceuticals Inc | 03/26/2024 |
3 | Crinetics Pharmaceuticals Stock Price Down 7.8 percent - MarketBeat | 04/12/2024 |
4 | Disposition of 20000 shares by Struthers Richard Scott of Crinetics Pharmaceuticals at 1.91 subject to Rule 16b-3 | 04/15/2024 |
5 | Crinetics Pharmaceuticals executive sells shares worth over 639k | 04/17/2024 |
6 | Investors in Crinetics Pharmaceuticals have seen stellar returns of 142 percent over the past three years | 04/25/2024 |
7 | Disposition of 2359 shares by Jeff Knight of Crinetics Pharmaceuticals at 45. subject to Rule 16b-3 | 04/29/2024 |
8 | Crinetics Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024 | 05/02/2024 |
9 | Fisher Asset Management LLC Acquires 387,033 Shares of Crinetics Pharmaceuticals, Inc. - MarketBeat | 05/06/2024 |
10 | 05/08/2024 |
11 | Crinetics Pharmaceuticals Inc Reports Q1 2024 Financial Results | 05/10/2024 |
12 | Crinetics Pharmaceuticals executive sells 148k in company stock | 05/14/2024 |
Begin Period Cash Flow | 32.7 M |
Crinetics |
Crinetics Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 3,631 in Crinetics Pharmaceuticals on February 14, 2024 and sell it today you would earn a total of 1,307 from holding Crinetics Pharmaceuticals or generate 36.0% return on investment over 90 days. Crinetics Pharmaceuticals is currently generating 0.565% in daily expected returns and assumes 4.023% risk (volatility on return distribution) over the 90 days horizon. In different words, 35% of stocks are less volatile than Crinetics, and 89% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
Risk |
Crinetics Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Crinetics Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Crinetics Pharmaceuticals, and traders can use it to determine the average amount a Crinetics Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1404
Best Portfolio | Best Equity | |||
Good Returns | ||||
Average Returns | ||||
Small Returns | CRNX | |||
Cash | Small Risk | Average Risk | High Risk | Huge Risk |
Negative Returns |
Estimated Market Risk
4.02 actual daily | 35 65% of assets are more volatile |
Expected Return
0.56 actual daily | 11 89% of assets have higher returns |
Risk-Adjusted Return
0.14 actual daily | 10 90% of assets perform better |
Based on monthly moving average Crinetics Pharmaceuticals is performing at about 10% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Crinetics Pharmaceuticals by adding it to a well-diversified portfolio.
Crinetics Pharmaceuticals Fundamentals Growth
Crinetics Stock prices reflect investors' perceptions of the future prospects and financial health of Crinetics Pharmaceuticals, and Crinetics Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Crinetics Stock performance.
Return On Equity | -0.5 | ||||
Return On Asset | -0.28 | ||||
Operating Margin | (55.47) % | ||||
Current Valuation | 2.93 B | ||||
Shares Outstanding | 78.86 M | ||||
Price To Earning | (12.03) X | ||||
Price To Book | 6.45 X | ||||
Price To Sales | 865.90 X | ||||
Revenue | 4.01 M | ||||
Gross Profit | (125.49 M) | ||||
EBITDA | (221.51 M) | ||||
Net Income | (214.53 M) | ||||
Cash And Equivalents | 408.51 M | ||||
Cash Per Share | 7.60 X | ||||
Total Debt | 51.73 M | ||||
Debt To Equity | 0.01 % | ||||
Current Ratio | 15.94 X | ||||
Book Value Per Share | 11.14 X | ||||
Cash Flow From Operations | (166.31 M) | ||||
Earnings Per Share | (3.77) X | ||||
Market Capitalization | 3.79 B | ||||
Total Asset | 635.35 M | ||||
Retained Earnings | (653.7 M) | ||||
Working Capital | 530.21 M | ||||
Current Asset | 44.96 M | ||||
Current Liabilities | 2.41 M | ||||
About Crinetics Pharmaceuticals Performance
To evaluate Crinetics Pharmaceuticals Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Crinetics Pharmaceuticals generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Crinetics Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Crinetics Pharmaceuticals market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Crinetics's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.Last Reported | Projected for Next Year | ||
Days Of Inventory On Hand | 2.1 K | 2.2 K | |
Return On Tangible Assets | (0.34) | (0.35) | |
Return On Capital Employed | (0.38) | (0.40) | |
Return On Assets | (0.34) | (0.35) | |
Return On Equity | (0.40) | (0.38) |
Things to note about Crinetics Pharmaceuticals performance evaluation
Checking the ongoing alerts about Crinetics Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Crinetics Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.Crinetics Pharmaceuticals appears to be risky and price may revert if volatility continues | |
The company reported the previous year's revenue of 4.01 M. Net Loss for the year was (214.53 M) with loss before overhead, payroll, taxes, and interest of (125.49 M). | |
Crinetics Pharmaceuticals currently holds about 408.51 M in cash with (166.31 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.6. | |
Over 98.0% of the company shares are held by institutions such as insurance companies | |
Latest headline from investing.com: Crinetics Pharmaceuticals executive sells 148k in company stock |
- Analyzing Crinetics Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Crinetics Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Crinetics Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Crinetics Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Crinetics Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Crinetics Pharmaceuticals' stock. These opinions can provide insight into Crinetics Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Crinetics Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Crinetics Stock please use our How to Invest in Crinetics Pharmaceuticals guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Complementary Tools for Crinetics Stock analysis
When running Crinetics Pharmaceuticals' price analysis, check to measure Crinetics Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crinetics Pharmaceuticals is operating at the current time. Most of Crinetics Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Crinetics Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crinetics Pharmaceuticals' price. Additionally, you may evaluate how the addition of Crinetics Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |
Is Crinetics Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Crinetics Pharmaceuticals. If investors know Crinetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Crinetics Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.77) | Revenue Per Share 0.069 | Quarterly Revenue Growth (1.00) | Return On Assets (0.28) | Return On Equity (0.50) |
The market value of Crinetics Pharmaceuticals is measured differently than its book value, which is the value of Crinetics that is recorded on the company's balance sheet. Investors also form their own opinion of Crinetics Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Crinetics Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Crinetics Pharmaceuticals' market value can be influenced by many factors that don't directly affect Crinetics Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Crinetics Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Crinetics Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Crinetics Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.